Key facts
- Notable investors include OVNI Capital, Xplore (Germany), Xpreneurs.
- Status: Privately Held (backing).
Investors
3- ·The complete investor list — 3 names
- ·Watchlist + deal alerts for Qtas (Decision/Risk Analysis)
- ·The full record, as it builds
Funding rounds
No funding rounds for Qtas (Decision/Risk Analysis) are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Qtas (Decision/Risk Analysis)
Operator of a MedTech startup intended to develop next-generation quantum sensing technologies for liquid biopsies to improve the detection and characterization of biomarkers. The company offers ultra-sensitive quantum sensing platforms for blood and cerebrospinal fluid analysis, enabling customers to perform sensitive downstream analyses such as single-cell sequencing and molecular profiling for neuro-oncological applications.
- Sector
- Healthcare
- HQ
- Munich, Germany
- Founded
- 2025
- Employees
- 9
- Website
- qtas.io/
- Ownership
- Privately Held (backing)
Qtas (Decision/Risk Analysis) doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Qtas (Decision/Risk Analysis) shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Qtas (Decision/Risk Analysis) in its N-PORT filings yet. We sweep new filings monthly.